Although ERBB2-targeted therapies, such as lapatinib, revolutionized management of ERBB2-overexpressing breast cancer, primary and acquired resistance remains a major obstacle for the cure of this deadly disease. This evidence concerns the gene ERBB2 and breast cancer.